ISOXSUPRINE HYDROCHLORIDE - isoxsuprine hydrochloride tablet 
Bi-Coastal Pharmaceutical Corporation

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Rx Only

DESCRIPTION

Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with the following chemical structure:

C H NO – HCl

p-Hydroxy-a[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol hydrochloride.

INDICATIONS

Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows:

Possibly Effective

  1. For the relief of symptoms associated with cerebrovascular insufficiency.
  2. In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease.

Final classification of the less-than-effective indications requires further investigation.

CONTRAINDICATIONS

There are no known contraindications to oral use when administered in recommended doses.

Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.

ADVERSE REACTIONS

On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued.

Although available evidence suggests a temporal association of these reactions with Isoxsuprine Hydrochloride, a causal relationship can be neither confirmed nor refuted.

Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrocholoride have been used to inhibit pre-term labor.

Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received Isoxsuprine Hydrochloride. Pulmonary edema has been reported in mothers treated with beta stimulants. Isoxsuprine Hydrochloride is neither approved nor recommended for use in the treatment of premature labor.

DOSAGE AND ADMINISTRATION

Oral: 10 to 20 mg, three or four times daily.

HOW SUPPLIED

Isoxsuprine HCl tablets, USP 10 mg
Bottles of 100 NDC 42582-100-10

PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label

Bi-Coastal
Pharmaceutical Corp.
®

NDC 42582-100-10

Isoxsuprine
Hydrochloride
Tablets, USP

10 mg

Rx only

100 Tablets

PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label

ISOXSUPRINE HYDROCHLORIDE 
isoxsuprine hydrochloride tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:42582-100
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
isoxsuprine hydrochloride (Isoxsuprine) isoxsuprine hydrochloride10 mg
Inactive Ingredients
Ingredient NameStrength
Lactose Monohydrate 
Magnesium Stearate 
Cellulose, Microcrystalline 
Starch, Corn 
Product Characteristics
ColorWHITE (White) Score2 pieces
ShapeROUND (Tablet) Size8mm
FlavorImprint Code I10
Contains    
Packaging
#Item CodePackage DescriptionMultilevel Packaging
1NDC:42582-100-10100 TABLET ( TABLET) in 1 BOTTLENone

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
UNAPPROVED DRUG OTHER06/02/2011

Labeler - Bi-Coastal Pharmaceutical Corporation (808397079)
Establishment
NameAddressID/FEIOperations
ECI Pharmaceuticals, LLC962476029MANUFACTURE, LABEL, ANALYSIS

Revised: 05/2011 Bi-Coastal Pharmaceutical Corporation